COVID-19 has left its mark on medtech. Is it long-term? Experts think there’s no doubt the pandemic will continue to influence medtech business decisions in the coming months and years according to an in-depth MedTechDive article identifying five impacted areas:

• Consumer campaigns to stop medical distancing and promote products and services have been designed to expand telehealth. Long-term reimbursement and patient confidentiality still remain a concern.

• Companies are offering employees flexible work arrangements to reduce on-site personnel and future real estate needs. Yet, desirable brick-and-mortar office environments are a consideration for attracting top job candidates.

• Long-term use of remote programming and monitoring technology has been shown to drive down healthcare costs and increase patient access to care.

• Virtual tech acceleration of remote clinical trial capabilities has fast-forwarded the market by at least five years.

• By far the biggest impact is the FDA’s decision in August that no longer requires premarket review for all laboratory-developed tests, not just for COVID-19 diagnostics.

Find out more about these beneficial gains that have a promising future.  

READ MEDTECHDIVE ARTICLE